34923-98-3

Basic information

• Product Name: 4-(P-HYDROXYANILINO)QUINAZOLINE
• Synonyms: 4-(P-HYDROXYANILINO)QUINAZOLINE;4-[(quinazolin-4-yl)amino]phenol
• CAS NO: 34923-98-3
• Molecular Formula: C₁₄H₁₁N₃O
• Molecular Weight: 237.26
• Mol File: 34923-98-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(P-HYDROXYANILINO)QUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(P-HYDROXYANILINO)QUINAZOLINE(34923-98-3)
• EPA Substance Registry System: 4-(P-HYDROXYANILINO)QUINAZOLINE(34923-98-3)

Safety Data

• Hazardous Substances Data: 34923-98-3(Hazardous Substances Data)

Upstream product

• 77725-90-7 4-(p-benzyloxyphenyl)aminoquinazoline 
• 491-36-1 4-Hydroxyquinazoline 
• 5190-68-1 4-chloroquinazoline 
• 42366-35-8 hydroxyimino-N-phenylacetamide 
• 91-56-5 indole-2,3-dione 
• 607-28-3 3-(hydroxyimino)indolin-2-one 
• 36185-83-8 N'-(2-cyanophenyl)-N,N-dimethylimidoformamide 
• 123-30-8 4-amino-phenol 
• 62-53-3 aniline 
• 100-02-7 4-nitro-phenol 
• 880-03-5 4-(methoxymethoxy)-1-nitrobenzene 
• 876-30-2 4-methoxymethyloxyaniline 

Downstream Products

• 72700-30-2 4-(3'-pyrrolidinylmethyl-4'-hydroxyanilino)quinazoline 
• 77725-96-3 4-(3'-hexahydropyridinylmethyl-4'-hydroxyanilino)quinazoline 
• 77725-97-4 2-(4-Methyl-piperazin-1-ylmethyl)-4-(quinazolin-4-ylamino)-phenol 
• 77725-98-5 1-[2-Hydroxy-5-(quinazolin-4-ylamino)-benzyl]-4-phenyl-piperidin-4-ol 
• 77729-08-9 4-(4'-hydroxy-3'-diethylaminomethylphenyl)aminoquinazoline 
• 72063-47-9 Changrolin 

Relevant articles and documents

Synthesis and Biological Evaluation of Novel Substituted 4-Anilinoquinazolines as Antitumor Agents

Eleven novel 4-anilinoquinazoline derivatives were synthesized and evaluated for their in?vitro antiproliferative activity. Among them, compound 9a exhibited the best potency, with IC50 values of 25?682?nm against various types of cancer cell l

Synthesis and biological evaluation of quinazoline derivatives – A SAR study of novel inhibitors of ABCG2

Multidrug resistance (MDR) is a major obstacle for effective chemotherapeutic treatment of cancer frequently leading to failure of the therapy. MDR is often associated with the overexpression of ABC transport proteins like ABCB1 or ABCG2 which efflux harmful substances out of cells at the cost of ATP hydrolysis. One way to overcome MDR is to apply potent inhibitors of ABC transporters to restore the sensitivity of the cells toward cytostatic agents. This study focusses on the synthesis and evaluation of novel 2,4-disubstituted quinazoline derivatives regarding the structure-activity-relationship (SAR), their ability to reverse MDR and their mode of interaction with ABCG2. Hence, the inhibitory potency and selectivity toward ABCG2 was determined. Moreover, the intrinsic cytotoxicity and the reversal of MDR were investigated. Interaction type studies with the substrate Hoechst 33342 and conformational analyses of ABCG2 with 5D3 monoclonal antibody were performed for a better understanding of the underlying mechanisms. In our study we could further enhance the inhibitory effect against ABCG2 (compound 31, IC50: 55 nM) and identify the structural features that are crucial for inhibitory potency, the impact on transport activity and binding to the protein.

Phthalazine compounds, compositions and use

The present invention relates to new compounds of the formula STR1 alkylene, or --S-- where R1 is hydrogen, alkyl, or aryl; W is hydrogen, hydroxy, amino, alkyloxy, aryloxy, O-alkyl, or O-aralkyl; (Y)A is --CH2 NR2/s